New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline

Core Insights - Novartis will present new data from 33 abstracts related to its Cardiovascular, Renal, and Metabolic (CRM) disease portfolio at the upcoming ASN Kidney Week 2025 and AHA Scientific Sessions 2025, showcasing its commitment to advancing therapies for heart and kidney conditions [1][2] Group 1: Presentation Highlights - The data includes studies on both approved and investigational therapies, emphasizing Novartis's dedication to providing meaningful solutions for patients with various CRM diseases [2] - Key highlights from ASN include analyses of Fabhalta and Vanrafia Phase III studies, real-world treatment patterns for Fabhalta, and C3 glomerulopathy studies that reinforce Fabhalta's long-term safety and efficacy [4][3] - AHA presentations will cover the impact of inclisiran-based treatment strategies on quality of life and muscle-related pain, as well as adherence and goal attainment data supporting inclisiran's addition to lipid-lowering therapy [5][4] Group 2: Product Information - Novartis is focused on redefining the approach to CRM conditions, leveraging a robust portfolio and pipeline to address significant unmet needs in cardiovascular and renal health [7] - The company has a 40-year legacy in cardiovascular care and is expanding its portfolio to target underlying causes of kidney diseases, aiming to transform outcomes and improve lives for patients with CRM diseases [7][9]